SEC Tracker
Get the app

Lisata Therapeutics LSTA

Lisata Therapeutics adds Jeff Farrow to board

Form
8-K
Filed
Importance
Major
  1. Board expanded from 7 to 8 members
  2. Jeff Farrow appointed as Class III director
  3. Farrow also joins Audit Committee
  4. Farrow has 15+ years of public-company financial leadership

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Lisata Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Nanoviricides NNVC public float $24M, Dec 31, 2025
  2. Tenax Therapeutics TENX public float $24M, Jun 30, 2025
  3. Aytu Biopharma AYTU public float $24M, Dec 31, 2025
  4. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old
  5. Scynexis SCYX public float $26M, Jun 30, 2025